- Home
- CAH vs EW Comparison
CAH vs EW Comparison
Compare CAH & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAH
- EW
- Stock Information
- Founded
- CAH 1979
- EW 1958
- Country
- CAH United States
- EW United States
- Employees
- CAH N/A
- EW N/A
- Industry
- CAH Other Pharmaceuticals
- EW Industrial Specialties
- Sector
- CAH Health Care
- EW Health Care
- Exchange
- CAH Nasdaq
- EW Nasdaq
- Market Cap
- CAH 48.4B
- EW 45.5B
- IPO Year
- CAH N/A
- EW 2000
- Fundamental
- Price
- CAH $207.24
- EW $85.27
- Analyst Decision
- CAH Buy
- EW Buy
- Analyst Count
- CAH 11
- EW 19
- Target Price
- CAH $196.36
- EW $92.35
- AVG Volume (30 Days)
- CAH 2.7M
- EW 5.2M
- Earning Date
- CAH 10-30-2025
- EW 10-30-2025
- Dividend Yield
- CAH 0.99%
- EW N/A
- EPS Growth
- CAH 27.25
- EW N/A
- EPS
- CAH 6.63
- EW 2.33
- Revenue
- CAH $234,310,000,000.00
- EW $5,883,800,000.00
- Revenue This Year
- CAH $15.26
- EW $13.96
- Revenue Next Year
- CAH $8.34
- EW $9.81
- P/E Ratio
- CAH $31.23
- EW $36.19
- Revenue Growth
- CAH 4.39
- EW 10.60
- 52 Week Low
- CAH $114.60
- EW $65.94
- 52 Week High
- CAH $208.32
- EW $87.21
- Technical
- Relative Strength Index (RSI)
- CAH 86.87
- EW 64.63
- Support Level
- CAH $203.84
- EW $82.01
- Resistance Level
- CAH $208.32
- EW $87.21
- Average True Range (ATR)
- CAH 4.68
- EW 2.14
- MACD
- CAH 0.38
- EW 0.00
- Stochastic Oscillator
- CAH 95.19
- EW 72.79
About CAH Cardinal Health Inc.
Cardinal Health is one of three leading pharmaceutical wholesalers in the US, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. Cardinal, Cencora, and McKesson hold well over 90% of the US pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
About EW Edwards Lifesciences Corporation
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.